Innova Vascular

Executive Summary

Innova Vascular is a private medical device company focused on developing minimally invasive solutions for vascular thromboembolism, a condition that includes deep vein thrombosis and pulmonary embolism. Headquartered in Irvine, California, the company operates within the Southern California medtech hub. Its lead product, the Laguna Thrombectomy System, has received FDA 510(k) clearance for use in the peripheral vasculature, positioning it as a potential competitor to existing thrombectomy devices. The system is designed to efficiently remove blood clots with reduced trauma, leveraging novel catheter-based technology. With FDA clearance achieved, Innova Vascular is transitioning from development to early commercialization, targeting interventional radiologists and vascular surgeons. The company has not disclosed funding rounds or valuation, but its cleared product and focused strategy suggest a measured go-to-market approach. As a private entity, Innova Vascular's progress will depend on successful market adoption, clinical evidence generation, and potential strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026First-in-human study initiation for Laguna Thrombectomy System in new indication (e.g., pulmonary embolism)70% success
• Q4 2026Announcement of strategic partnership or distribution agreement for U.S. commercialization60% success
• Q1 2027Publication of initial clinical data or case series demonstrating safety and efficacy in peripheral use80% success